Vaccine Derived Poliovirus (VDPV)

dc.contributor.authorMohanty, Aroop
dc.contributor.authorRohilla, Ranjana
dc.contributor.authorZaman, Kamran
dc.contributor.authorHada, Vivek
dc.contributor.authorDhakal, Surakchhya
dc.contributor.authorShah, Abhishek
dc.contributor.authorPadhi, Bijaya Kumar
dc.contributor.authorAl-qaim, Zahra Haleem
dc.contributor.authorAltawfiq, Kauthar Jaffar A.
dc.contributor.authorTirupathi, Raghavendra
dc.contributor.authorSah, Ranjit
dc.contributor.authorAl-Tawfiq, Jaffar A.
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-01-26T15:15:03Z
dc.date.available2024-01-26T15:15:03Z
dc.date.issued2023-06-01
dc.description.abstractPoliomyelitis is caused by Poliovirus, a member of a large group of enteroviruses. Vaccine-derived polioviruses (VDPVs) stem from mutated live poliovirus, which is contained in the Oral Polio Virus vaccine (OPV). In addition, the emergence of VDPV is one of the global challenges for the eradication of poliomyelitis. VDPVs continue to affect different parts of the world; 1081 cases occurred in 2020 and 682 cases in 2021. There are several reasons that may have caused the increase in circulating vaccine-derived poliovirus (cVDPV) after the “switch” from the trivalent to the bivalent oral polio vaccine. One reason is the low vaccination rate among the targeted population, which has been further aggravated by the COVID-19 pandemic. Several strategies could control the spread of VDPV including the use of the monovalent OPV (mOPV-2). The risk of VDPV can be minimized through increased immunization rates and the use of safer vaccine alternatives. The global effort to eradicate polio has made significant progress over the years, but continued vigilance and investment in immunization programs are needed to achieve the ultimate goal of a polio-free world.
dc.eprint.versionFinal published version
dc.identifier.citationMohanty A, Rohilla R, Zaman K, et al. Vaccine Derived Poliovirus (VDPV). Infez Med. 2023;31(2):174-185. Published 2023 Jun 1. doi:10.53854/liim-3102-5
dc.identifier.urihttps://hdl.handle.net/1805/38228
dc.language.isoen_US
dc.publisherDepartment of Medicine and Surgery, University of Salerno
dc.relation.isversionof10.53854/liim-3102-5
dc.relation.journalInfections in Medicine (Infez Med)
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectPoliovirus
dc.subjectVaccine derivative poliovirus
dc.titleVaccine Derived Poliovirus (VDPV)
dc.typeArticle
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241397/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
1124-9390_31_1_2023_174-185.pdf
Size:
1.72 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: